Topics
All Topics

In a recent issue brief, HCCI found that the already high cost of care for people with multiple sclerosis (MS) rose dramatically over the past several years. The primary driver was the increasing cost of a small group of prescription drugs called Disease Modifying Therapies (DMTs). To illustrate the role prescription drug prices play in driving overall health care spending for people with MS, we d...

By: John Gregory  Between 2009 and 2015, spending on patients with multiple sclerosis (MS) greatly increased, with disease modifying therapies (DMTs) accounting for 82 percent of that increase as prices jumped every year and use slightly declined. The report from the Health Care Cost Institute (HCCI) examined claims for people with MS from 2009 to 2015 covered by individual market, employer-s...

This issue brief investigates how the cost of prescription drugs affects the total cost of care for people with multiple sclerosis (MS). It decomposes total health care spending by category, specifically separating out spending on specialty drugs used to treat MS, called Disease Modifying Therapies (DMTs). The issue brief subsequently examines whether changes in spending on DMTs are due to changes...